Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
grn-1201
- Development stage
- Phase 1
- Lead developer
- BrightPath Biotherapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
GRN-1201 is a cancer peptide vaccine developed to stimulate the immune system against tumor-associated antigens (TAAs). It consists of four HLA-A*02-restricted peptides derived from four distinct TAAs commonly expressed in melanoma and other cancers. The vaccine is designed to activate cytotoxic T lymphocytes (CTLs) that specifically target and kill cancer cells presenting these antigens. Clinical development focused on melanoma and non-small cell lung cancer (NSCLC), both as monotherapy and in combination with immune checkpoint inhibitors such as pembrolizumab. The developer, BrightPath Biotherapeutics, discontinued Phase 2 clinical trials in 2023 due to challenges including slow enrollment and evolving treatment standards[2][4][6][7].
02
Targets
HLA-A (HLA class I histocompatibility antigen A alpha chain)TCR (T cell antigen receptor complex)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on grn-1201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on grn-1201.